On April 10, 2025, the U.S. Food and Drug Administration (FDA) announced it will be phasing out the current requirements for animal testing in the development of monoclonal antibody therapies and ...

Monoclonal antibodies (mAbs) are nature's biological warheads, able to target and help eliminate foreign or abnormal agents from the body. In theory, replicating this powerful defense system could ...

Due to their extraordinary specificity and pharmacokinetic (PK) behavior, human immunoglobulin gamma monoclonal antibodies (hIgG ... process and occurs in the acid environment of early epithelial ...

The potential of monoclonal antibodies (mAbs) as therapies is indisputable. The current mAbs market is expected to be around ~USD 150 billion. In 2021, five out of the top 10 selling drugs were ...

This is a groundbreaking step toward advancing public health by using more effective and human-relevant methods instead of animal testing The FDA announced that is going to be replacing animal testing ...

The latter occurs most notably in the neonate as a result of a mother with antibodies due to AITD. TPO antibodies (TPOAb) appear involved in the tissue destructive processes associated with the ...

Despite its vital role in "kick-starting" the immune response, IgD is arguably the least understood antibody, with little known about how it might participate in other parts of the immune system. A ...

Methods: Following the isolation of plasmablasts from vaccinees, the OMV-specific human monoclonal antibodies (HumAbs) were recombinantly expressed and characterized for their binding and functional ...

Real time quote data is not available at this time. *Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green ...